Edition:
United Kingdom

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

1.50USD
7:28pm GMT
Change (% chg)

$-0.09 (-5.97%)
Prev Close
$1.59
Open
$1.56
Day's High
$1.67
Day's Low
$1.49
Volume
42,237
Avg. Vol
87,634
52-wk High
$15.27
52-wk Low
$1.49

Summary

Name Age Since Current Position

Christy Shaffer

60 2012 Chairman of the Board

Daniel White

50 2011 President, Chief Executive Officer, Director

Charles Deignan

52 2012 Chief Financial Officer

Glenn Noronha

52 2016 Chief Scientific Officer

Leslie Zacks

49 2018 Chief Compliance Officer, General Counsel

Rafael Andino

Vice President - Engineering & Manufacturing

Thomas Crawford

2018 Vice President - Supply Chain

Carol Hoang

2018 Vice President - Medical Affairs

Viral Kansara

2018 Vice President - Discovery

Lester Rodriguez

2018 Vice President - Quality

Thomas Ciulla

2018 Chief Medical Officer

Jeffrey Edwards

58 2018 Director

George Lasezkay

65 2017 Director

Richard Croarkin

63 2016 Independent Director

William Humphries

51 2012 Independent Director

Clay Thorp

48 2012 Independent Director

Biographies

Name Description

Christy Shaffer

Dr. Christy L. Shaffer, Ph.D., is the Chairman of the Board of Clearside Biomedical, Inc. Since August 2015, Dr. Shaffer has served as a General Partner with Hatteras Venture Partners, an investment firm and from 2011 to August 2015 as a Venture Partner. Since 2011, Dr. Shaffer has also served as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010, Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the company’s first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999, as its President in 2005 and a member of its Development Committee in 2009. Prior to Inspire, she was a clinical research scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co. Dr. Shaffer currently serves in leadership roles on several non-profit boards, including as chair of the Morehead Planetarium and Science Center’s advisory board, on the Board of Trustees for the Cystic Fibrosis Foundation, and as chair of the board of CFF Therapeutic, Inc. Dr. Shaffer is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee’s Health Science Center in Memphis, Tennessee. She completed post-doctoral training at The Chicago Medical School as well as the University of North Carolina at Chapel Hill.

Daniel White

Mr. Daniel White is President, Chief Executive Officer, Director of Clearside Biomedical, Inc. From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009. From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company. In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology. Previously, he was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma. Mr. White holds an M.B.A. degree from Wake Forest University and a B.S. degree in Molecular Biology from Auburn University.

Charles Deignan

Mr. Charles Deignan is the Chief Financial Officer of Clearside Biomedical, Inc. From 2009 to December 2011, Mr. Deignan was Vice President of Finance and Administration for Salutria Pharmaceuticals. Previously, from 1999 to 2009, Mr. Deignan served in a number of roles with AtheroGenics, Inc., a publicly held biopharmaceutical company, including as its Vice President of Finance and Administration. Prior to that, he held management positions at AAIPharma, Inc. and Schering-Plough. Mr. Deignan received his B.S. degree in Business Administration from Boston University.

Glenn Noronha

Dr. Glenn Noronha, Ph.D., is the Chief Scientific Officer of Clearside Biomedical, IncFrom August 2012 to May 2013, he served as Vice President, Research and Development at Sucampo Pharma Americas, LLC, a pharmaceutical company. From July 2011 to July 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development. From 2008 to July 2011, Dr. Noronha was Global Project Head for Retinal Development at Alcon Laboratories, Inc., a Novartis company. From 2002 to 2008, Dr. Noronha held several positions at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs. Previously, from 2000 to 2002, he was a research scientist and project leader for Medtronic MiniMed, Inc. Dr. Noronha received his Ph.D. degree from Loyola University of Chicago and was a post-doctoral fellow at the University of California at Irvine.

Leslie Zacks

Mr. Leslie Zacks is Chief Compliance Officer, General Counsel of the Company. In a distinguished legal career spanning more than 24 years, Mr. Zacks most recently served as Vice President, General Counsel and Chief Compliance Officer at Arbor Pharmaceuticals, Inc., where he provided strategic counsel on legal, intellectual property and compliance issues. Prior to joining Arbor, Mr. Zacks was Executive Vice President, General Counsel and Chief Compliance Officer at Shionogi Pharma, Inc. from 2004 to 2010. From 2002 to 2004, he worked at Hunton & Williams, LLP, where he was a partner in the Intellectual Property Litigation department. Mr. Zacks is a registered patent attorney who has held associate positions at Powell, Goldstein, Frazer & Murphy, LLP and at Webb, Carlock, Copeland, Semler and Stair, LLP. Mr. Zacks holds a J.D. and a B.A. in English from the University of Florida.

Rafael Andino

Mr. Rafael V. Andino is the Vice President - Engineering & Manufacturing at Clearside Biomedical, Inc. Mr. Andino has 25 years of experience in the pharmaceutical and medical device industry in both public and private companies serving in product development, research and development and general management roles. He has led multidisciplinary and multinational teams to launch products in many fields of medicine including ophthalmology, urology, endourology, gynecology, wound care, cardiovascular and general surgery. Prior to Bard, he founded and led Biofisica, Inc. Prior to founding Biofisica, Mr. Andino was an R&D director and senior project manager for CIBA VISION (a Novartis company). He has also worked for the global technology companies E.I. Dupont de Nemours, General Electric and IBM. Mr. Andino obtained a Bachelor’s degree in Mechanical Engineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and an MBA from Mercer University in Atlanta, GA.

Thomas Crawford

Mr. Thomas Crawford is Vice President - Supply Chain of the Company. In a career spanning more than 25 years, Mr. Crawford has extensive expertise in supply chain management, trade relations, product launches, and manufacturing operations. Before joining Clearside, he was Vice President of Supply Chain and Customer Service for Pharma Tech Industries, LLC, the world's largest pharmaceutical contract manufacturer and packager of powder products. Mr. Crawford's earlier experience includes supply chain, manufacturing and trade relations management roles at various pharmaceutical and medical device companies, including Shionogi Inc., Immucor Inc., Aronex Pharmaceuticals Inc., Allergan, Inc., Abbot Laboratories and Zenith Goldline Pharmaceuticals, Inc.

Carol Hoang

Dr. Carol Hoang is Vice President - Medical Affairs of the Company. Dr. Hoang brings over 17 years of experience across multiple sectors of the global healthcare industry to Clearside. Prior to joining Clearside, Dr. Hoang was Vice President, Medical Affairs for DigiSight Technologies, Inc., a digital health company developing mobile solutions to enhance vision care for patients and doctors. Previously, she served as Global Executive Medical Director at Novartis Pharma AG, leading global medical strategy in ophthalmology. Before joining Novartis, she held senior marketing and medical affairs positions at Genentech, Inc., where she helped launch Lucentis in 2006. Dr. Hoang’s previous experience includes various roles at Oncology Therapeutics Network, a subsidiary of Bristol-Myers Squibb Company, and at CVS Caremark, the prescription benefit management subsidiary of CVS Health. Dr. Hoang earned her dual Pharm.D/MBA degree from the University of Southern California.

Viral Kansara

Mr. Viral Kansara is Vice President - Discovery of the Company. Dr. Kansara brings over 12 years of experience and expertise in ophthalmic drug discovery, development and delivery to Clearside. Prior to joining Clearside, Dr. Kansara was Global Team Leader and Head of the Ocular Pharmacokinetic and Drug Delivery Lab in the Ophthalmology department at Novartis Institutes for Biomedical Research, Inc. At Novartis, Dr. Kansara's lab focused on leveraging multiple modalities (biologics, small molecules, gene therapy and long-acting platforms) for the discovery and development of novel treatment therapies for blinding diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Previously, he served as Senior Research Chemist, Pharm. Sciences and RNAi, at Merck & Co., Inc. and also completed a Graduate Research Collaboration with Alcon Research Ltd., focused on the delivery of therapies to the back of the eye. Dr. Kansara earned his Ph.D. in the field of Pharmaceutical Sciences from the University of Missouri-Kansas City and has authored two book chapters and numerous research articles.

Lester Rodriguez

Mr. Lester Rodriguez is Vice President - Quality of the Company. Mr. Rodríguez is an accomplished quality management professional with over 30 years of experience in the pharmaceuticals industry. Before joining Clearside, Mr. Rodríguez was Vice President of Quality for Pharma Tech Industries, the world's largest pharmaceutical contract manufacturer and packager of powder products. Mr. Rodríguez's earlier experience includes quality and manufacturing leadership roles at various pharmaceutical companies, including Ciba Vision, Novartis Ophthalmics and Shionogi, Inc.

Thomas Ciulla

Mr. Thomas A. Ciulla is Chief Medical Officer of the Company. Prior to joining Clearside, Dr. Ciulla served a VP role, as Medical Strategy Lead-Ophthalmology at Spark Therapeutics, where he defined and led medical strategy to support development and commercialization of Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease. He previously served a VP role, in Clinical Strategy at Ophthotech Corporation. Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research lab at Indiana University School of Medicine, the largest U.S. med school. He remains a volunteer Clinical Professor at the university and serves on the Board of Directors of Midwest Eye Institute. He is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology. Dr. Ciulla has held numerous leadership roles in clinical research, including principal investigator, medical monitor, and member of scientific advisory, data safety monitoring or writing committees in over 100 national clinical trials, including CATT and registration trials for nearly all retinal therapeutics approved by the FDA. He has served on journal editorial boards, edited several textbooks, presented at over 200 conferences, and co-authored over 200 publications, including the first published U.S.-based randomized clinical trial on any intravitreal therapy in neovascular AMD. Dr. Ciulla graduated from Harvard College and UCSF Med School, followed by an internship and residency at Harvard Med School, and a fellowship at Tufts Med School. He also earned an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine.

Jeffrey Edwards

Mr. Jeffrey L. Edwards is Director of the Company. He retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan’s Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas from 1992 to 1993 and Security Pacific National Bank from 1983 to 1992, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the board of directors of FibroGen, Inc. and Bio-Rad Laboratories, Inc., both of which are publicly traded biopharmaceutical companies. Mr. Edwards received a Bachelor of Arts in Sociology from Muhlenberg College and completed the Advanced Management Program at the Harvard Business School.

George Lasezkay

Dr. George Lasezkay, Pharm.D., J.D., serves as Director of the Company. Dr. Lasezkay has an accomplished history of success in the life sciences industry. For the past 15 years, he has served as an independent director on the boards of a number of domestic and foreign emerging biopharmaceutical companies, both public and private. Dr. Lasezkay currently serves on the board of directors of TheraVida, Inc., a clinical stage drug development company. Previously, Dr. Lasezkay served as Executive Vice President, General Counsel at Acucela Inc., a development stage company that specializes in identifying and developing novel ophthalmic therapeutics. For the 12 years prior to joining Acucela, he was President of Horizon Pharma Group, a private life sciences consultancy practice. Prior to his private consultancy practice, Dr. Lasezkay was Corporate Vice President for Corporate Development at Allergan, Inc., the global pharmaceutical and medical aesthetics company. His 13 years of progressive experience at Allergan includes a number of executive leadership positions, including being a member of the company’s Executive Committee, Assistant General Counsel for Commercial Affairs, and General Counsel for the Asia-Pacific Region. In these positions, he played a critical role in developing corporate strategy and was responsible for a wide variety of licensing, R&D collaboration and acquisition transactions involving new technologies, products and companies. Earning B.S. Pharmacy and Doctor of Pharmacy degrees from the State University of New York at Buffalo, and a J.D. degree from the Southern California Gould School of Law, Dr. Lasezkay also brings forward diverse knowledge and expertise in private firm and in-house legal practice, hospital pharmacy practice, clinical pharmacokinetics consultation and clinical drug research.

Richard Croarkin

Mr. Richard J. Croarkin is an Independent Director of the Company. From 2007 to 2010, Mr. Croarkin was the Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer of Alcon, Inc., a public ophthalmic pharmaceutical and medical device company. From 2011 through early 2013, Mr. Croarkin served as the Chief Financial Officer of Nestlé Health Science, S.A., a division of Nestlé focused on medicalized nutrition solutions for chronic medical conditions. Mr. Croarkin retired in early 2013. Mr. Croarkin currently serves on the board of directors and audit committee of Aerie Pharmaceuticals, Inc., a public clinical stage pharmaceutical company. Mr. Croarkin also occasionally serves as a panelist on the NASDAQ Listing Qualifications Panel, a panel that adjudicates appeals by companies that have received notification of delisting by the NASDAQ. In 2008 and 2009, Mr. Croarkin served as a director on the supervisory board of the German publicly traded company, Wave Light, A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Mr. Croarkin received his B.A. in economics from Georgetown University and his M.B.A. degree in finance from the University of Connecticut.

William Humphries

Mr. William D. Humphries is Biography of Clearside Biomedical, Inc. Since January 2017, he has served as Executive Vice President, Company Group Chairman for Dermatology of Valeant Pharmaceuticals International, Inc. From March 2012 to December 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2006 to March 2012, he served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel from 2009 until March 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business. Mr. Humphries currently serves on the board of Aclaris Therapeutics, Inc., a publicly traded company. Mr. Humphries has served on the board of ZARS Pharma, the GlaxoSmithKline Portfolio Investment Board and the GlaxoSmithKline Ophthalmology Board. Mr. Humphries received his M.B.A. degree from Pepperdine University and a B.A. degree from Bucknell University.

Clay Thorp

Mr. Clay B. Thorp is an Independent Director of Clearside Biomedical, Inc. In 2001, Mr. Thorp co-founded and has since served as General Partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. Previously, he was instrumental in the founding of several life sciences companies, including serving as co-founder, Chief Executive Officer and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005, co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc., co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000, and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp holds a Masters of Public Policy degree from Harvard University and a B.A. degree in Mathematics and History from the University of North Carolina at Chapel Hill.